The U.S. Supreme Court recently heard oral arguments about the FDA’s decision to remove patient safeguards for abortion-inducing drugs. Critics argue that the FDA failed to consider the medical and ethical dimensions of the issue, and point to the lack of sound scientific evidence supporting their actions. They also highlight the FDA’s failure to adequately report adverse events, emphasizing the potential risks to women’s health.